Verismo Therapeutics Unveils Groundbreaking KIR-CAR Data at AACR Annual Meeting 2026 At the AACR Annual Meeting 2026, Verismo Therapeutics will present promising Phase 1 data on its innovative KIR-CAR therapies, SynKIR™-110 and SynKIR™-310, highlighting advancements in immunotherapy for various cancers.

Verismo Therapeutics Unveils Groundbreaking KIR-CAR Data at AACR Annual Meeting 2026 #USA #San_Diego #Immuno-Oncology #Verismo_Therapeutics #SynKIR